Mezavant (Mesalazine)

Mesalazine acts locally in the intestinal lumen, inhibiting cyclooxygenase and lipoxygenase enzymes, which lowers prostaglandin and leukotriene production. It also scavenges free radicals, thereby decreasing oxidative stress and dampening the inflammatory response of the colonic mucosa.

The specific dose of Mezavant is determined by the prescribing clinician based on disease severity, patient weight, and response to therapy. Healthcare professionals tailor the regimen to each individual, and patients should follow the prescriber’s instructions without alteration.

Safety data for mesalazine in pregnancy and lactation are limited. Clinicians weigh potential benefits against risks before prescribing to pregnant or nursing women. Patients should discuss their situation with a healthcare provider to decide whether the medication is appropriate.

To request Mezavant, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Mezavant belongs to the 5‑ASA class, offering a topical anti‑inflammatory effect within the colon. Compared with systemic steroids, it has a more favorable safety profile for long‑term use. Biologic agents target immune pathways but are generally reserved for moderate‑to‑severe disease when 5‑ASA therapy is insufficient.

Mezavant should be stored at ambient temperature, below 25 °C, in its original packaging to protect it from moisture and light. Keep the product out of reach of children and avoid storing it in bathrooms or other humid environments.

Mezavant is taken orally, usually with water. The tablet (or other oral form) should be swallowed whole unless the prescribing information advises otherwise. Patients should follow the dosing schedule provided by their healthcare professional and not crush or split the tablet without guidance.

Serious adverse events, though uncommon, include severe allergic reactions such as anaphylaxis, myocarditis, and pancreatitis. Patients should seek immediate medical attention if they experience symptoms like difficulty breathing, chest pain, severe abdominal pain, or persistent vomiting.

Mezavant is contraindicated in individuals with known hypersensitivity to mesalazine, other 5‑ASA compounds, or any excipients in the formulation. It should also be avoided in patients with severe renal or hepatic impairment unless closely monitored by a specialist.